Clinical trials: Ticagrelor, open to volunteers
Vertebral Artery Stenosis
Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study
This is a prospective, multi-center, registry study exploring the duration of dual antiplatelet therapy (DAPT) after drug-eluting stent(DES) treatment of symptomatic vertebral artery atherosclerotic stenosis.
- Trial name
- M Short DAPT (NCT06683300)
- Testing
- DAPT for 3 months after vertebral artery stenting
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Beijing Tiantan Hospital
Peripheral Arterial Disease (PAD), Amputation
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore…
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- NCT07613840
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 484 people
- Sponsor
- Massachusetts General Hospital
Stroke, Transient Ischemic Attack (TIA)
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic…
- Trial name
- CYP-FAST (NCT06943586)
- Testing
- CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Alabama at Birmingham
Acute Coronary Syndrome
DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial
To test whether the polymer-free drug-coated stent (DCS) BioFreedom is noninferior to the biodegradable polymer drug-eluting stent (DES) Ultimaster in terms of 1-year patient-oriented composite endpoint (POCE, composite of…
- Trial name
- ONE-PASS (NCT05305482)
- Testing
- Drug-coated stent, Drug-eluting stent
- Where
- South Korea
- Volunteers
- 3,520 people
- Sponsor
- Yonsei University
Cardiac Surgery
Ticagrelor Hemoadsorption Using Cytosorb® for Reduction of Bleeding During Cardiac Surgery
Cardiac surgery is at high risk of intraoperative bleeding. Inhibitors of the P2Y12 platelet receptor, such as ticagrelor, are recommended in patients with acute coronary stroke (ACS) to reduce the incidence of major…
- Trial name
- TICAdSORB (NCT07822620)
- Testing
- Device: Cytosorb hemoadsorption
- Where
- France
- Volunteers
- 232 people
- Sponsor
- University Hospital, Rouen
Chronic Coronary Syndrome
Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease
This is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication (PROBE design), comparing one-month dual antiplatelet therapy (DAPT) with low-dose ticagrelor (60 mg BID) followed by ticagrelor…
- Trial name
- STELAR (NCT07080684)
- Testing
- Ticagrelor 60 mg, clopidogrel 75 mg
- Volunteers
- 1,000 people
- Sponsor
- University of Messina
Coronary Artery Disease
Ticagrelore Alone Post PCI
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in…
- Trial name
- TICALONE (NCT06509893)
- Testing
- aspirin 80 mg and clopidogrel 75 mg daily, Ticagrelor 90 MG
- Where
- 2 sites in Iran
- Volunteers
- 5,400 people
- Sponsor
- Shiraz University of Medical Sciences
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Among aneurysmal subarachnoid hemorrhage (aSAH) survivors, ischemic injuries such as peri procedural thromboembolic events (TEE) and delayed cerebral ischemia (DCI) represent the most important disabling complications.
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia, Endovascular Procedure
- Trial name
- TALISCHER-SAH (NCT07821008)
- Testing
- Experimental group: ticagrelor
- Where
- 7 sites in France
- Volunteers
- 274 people
- Sponsor
- University Hospital, Toulouse
Coronary Disease, Heart Diseases
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Myocardial Ischemia
- Trial name
- PIV-EPIC (NCT06535568)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- Italy
- Volunteers
- 576 people
- Sponsor
- Fondazione Ricerca e Innovazione Cardiovascolare ETS
Ischemic Stroke, Patent Foramen Ovale
Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
A registry of patients from the Asia-Pacific region with PFO and ischemic stroke, designed to study the characteristics, investigations, treatment and outcomes using real-world data.
- Trial name
- PACIFIC-PFO (NCT06983795)
- Testing
- PFO closure using approved PFO closure devices, Surgical PFO closure, Medical management
- Where
- Singapore
- Volunteers
- 1,000 people
- Sponsor
- National University Hospital, Singapore
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Dual Anti-platelet Therapy
Aspirin-Free Strategy After 3-6 Month Dual Antiplatelet Therapy in Acute Coronary Syndrome
This randomized controlled trial aims to evaluate the safety and efficacy of an aspirin-free strategy after 3-6 months of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) who have undergone complete…
- Trial name
- NCT07736196
- Testing
- Aspirin-Free Strategy, Dual Antiplatelet Therapy
- Where
- Egypt
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Assiut University
Carotid Endarterectomy, Carotid Stenting
Carotid Endarterectomy and Stenting Timing
To compare the safety and efficacy of carotid revascularization performed within 48 hours versus after 14 days in patients with symptomatic carotid stenosis accompanied with MRI-confirmed acute infarction (high signal on…
- Trial name
- CEST (NCT06898151)
- Testing
- CEA/CAS plus best medical treatment
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Xuanwu Hospital, Beijing
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
The MATE study is a randomized, multicenter, open-label, investigator-initiated clinical trial aimed to evaluate efficacy and safety of sequential monotherapy of ticagrelor and clopidogrel in patients with acute coronary syndrome…
- Trial name
- MATE (NCT04937699)
- Testing
- Standard-DAPT of Ticagrelor plus aspirin, Sequential monotherapy of Ticagrelor and clopidogrel
- Where
- China
- Volunteers
- 2,690 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Intracranial Aneurysm
A Multicenter Prospective Study of New Flow Diverter Stent on the Treatment of Intracranial Aneurysms in China
Intracranial aneurysm, as a common cerebrovascular disease, has a variety of treatment methods, including surgical treatment and endovascular treatment.
- Trial name
- APRESENT (NCT07821957)
- Testing
- Novel Flow Diverter Stent
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Beijing Tiantan Hospital
ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone…
- Conditions
- ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, Stroke
- Trial name
- DREAM-PRIDE (NCT04948749)
- Testing
- Drug Eluting Stent implantation, Aggressive medical treatment, Risk factor management
- Where
- 18 sites in China
- Volunteers
- 358 people
- Sponsor
- Beijing Tiantan Hospital
Symptomatic Non-acute Intracranial Artery Occlusion, Ischemic Stroke
Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR）
A multicenter, randomized, open-label, endpoint-blinded trial to compare the effects of endovascular recanalization plus aggressive medical management with aggressive medical management alone on stroke recurrence and mortality in…
- Trial name
- NCT07495969
- Testing
- Endovascular Recanalization Strategy, Aggressive Medical Management
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Feng Gao
Coronary Heart Disease
Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
This study is designed to verify the safety and efficacy of Lepu® NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System combined with different antiplatelet therapies in the treatment of coronary heart disease.
- Trial name
- NCT04995159
- Testing
- Single anti-platelet therapy, Dual anti-platelet therapy
- Where
- 114 sites in China
- Volunteers
- 2,150 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Arterial Disease (CAD)
The Switching Antiplatelet-9 (SWAP-9) Study
The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).
- Trial name
- SWAP-9 (NCT06588595)
- Testing
- Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Antiphospholipid Syndrome, Arterial Thrombosis
Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
The goal of this registry is to gather more information on the efficacy and safety of various antithrombotic regimens. The registry collects data on patients with antiphospholipid syndrome and an arterial event within the past 12…
- Trial name
- NCT05646394
- Testing
- Dual antiplatelet therapy, Combined antithrombotic therapy, Vitamin K antagonist standard intensity
- Where
- 3 sites in Argentina, Canada
- Volunteers
- 150 people
- Sponsor
- McMaster University
Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation.
- Conditions
- Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease
- Trial name
- TAILOR-DAPT (NCT05732701)
- Testing
- Algorithm-guided DAPT duration, Standard-of-care DAPT duration
- Where
- 4 sites in Bosnia and Herzegovina, Italy and 1 more
- Volunteers
- 2,788 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern